Effect of Next Generation Pulsatile Mechanical Circulatory Support on Cardiac Mechanics: The PULSE Trial.
Marcelo B Bastos, Hannah McConkey, Oren Malkin...
https://pubmed.ncbi.nlm.nih.gov/35331637/Actively Recruiting
Led by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Updated on 2025-09-08
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating the safety and effectiveness of the iVAC 2L transaortic device, a temporary mechanical circulatory support MCS system, in patients with coronary artery disease undergoing high-risk percutaneous coronary intervention PCI. This procedure aims to stabilize heart function during PCI, especially in patients at risk of sudden circulatory collapse. The study focuses on outcomes such as death, heart attack, stroke, and transient ischemic attack during hospitalization and up to one year after the procedure. The iVAC 2L device includes an external membrane pump and a catheter inserted through the femoral artery into the left ventricle and ascending aorta. It works in sync with the heart cycle to assist blood flow by drawing blood during heart contraction and pushing it into the aorta during relaxation. The device is minimally invasive and designed to reduce complications compared to other mechanical support options. Patients will have the device placed before or during PCI and will be closely monitored throughout the procedure and afterward. Participants will have initial assessments including ECG, echocardiography, and blood tests to evaluate heart function and overall health. After device placement and PCI, patients will be observed in the intensive care unit and receive standard medical care during hospitalization. Researchers will track various safety and effectiveness outcomes, including heart function, vascular complications, and incidents of heart attack or stroke, with follow-up continuing for 360 days after the procedure.
CONDITIONS
Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI
O
Oleg Dorogun, MD
E
Eric Avetisyan, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 40 to 270 minutes
Participants undergo placement of the iVAC 2L transaortic device during high-risk percutaneous coronary intervention (PCI) to provide temporary mechanical circulatory support.
1 visit (in-person, during PCI procedure)
Duration - Up to 7 days or until discharge, if earlier
Participants receive monitoring and care in the intensive care unit immediately after the PCI and device placement according to clinical practice guidelines.
Continuous monitoring during hospitalization
Duration - Up to 360 days after PCI
Participants are followed for clinical outcomes including mortality, myocardial infarction, stroke, and other complications up to one year after the procedure.
1 visit at day 7 or discharge and 1 visit at day 360
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Marcelo B Bastos, Hannah McConkey, Oren Malkin...
https://pubmed.ncbi.nlm.nih.gov/35331637/Josko Bulum, Marcelo B Bastos, Ota Hlinomaz...
https://pubmed.ncbi.nlm.nih.gov/39336843/Marcelo B Bastos, Maarten P van Wiechen, Nicolas M Van Mieghem
https://pubmed.ncbi.nlm.nih.gov/31934785/Alexander Samol, Marcus Wiemer, Sven Kaese
https://pubmed.ncbi.nlm.nih.gov/35597491/Corstiaan A den Uil, Joost Daemen, Mattie J Lenzen...
https://pubmed.ncbi.nlm.nih.gov/28216471/Koen Ameloot, Marcelo B Bastos, Joost Daemen...
https://pubmed.ncbi.nlm.nih.gov/30741638/National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Lead Sponsor